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Objectives. The purpose of this study was to determine whether
contrast-enhanced transthoracic echocardiography improves the
evaluation of left ventricular (LV) volumes and ejection fraction
(EF).
Background. Echocardiographic assessment of LV volumes and
EF is widely used but may be inaccurate when the endocardium is
not completely visualized. Recently the intravenous (IV) admin-
istration of perfluorocarbon microbubbles has been shown to
enhance opacification of the LV cavity, but the utility of these
agents to improve the echocardiographic assessment of LV sys-
tolic function is unknown.
Methods. In 40 subjects (29 men and 11 women, aged 24 to 81
years) an assessment of LV volumes and EF was performed with
a magnetic resonance imaging examination, followed immediately
by a transthoracic echocardiogram before and after the intrave-
nous administration of 2% dodecafluoropentane emulsion (Echo-
Gen; Sonus Pharmaceuticals, Bothell, Washington).
Results. Contrast enhanced the echocardiographic assessment
of LV end diastolic volume (p < 0.02), end systolic volume (p <
0.01) and LVEF (p < 0.03). The percentage of subjects in whom
the correct echocardiographic classification EF was normal, mild
to moderately depressed or severely reduced improved signifi-
cantly after contrast enhancement (from 71% before contrast to
94% after, p < 0.03). These findings were most striking in the
subjects with two or more adjacent endocardial segments not
visualized at baseline.
Conclusions. Administration of an intravenous contrast agent
improves the ability to accurately assess LV volumes and EF in
humans. Contrast enhancement is most useful in subjects with
two or more adjacent endocardial segments not seen at baseline.
(J Am Coll Cardiol 1998;32:1426–32)
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Measurement of left ventricular (LV) volumes and systolic
function provides valuable diagnostic and prognostic informa-
tion in patients with cardiovascular disease. Although echocar-
diography is used widely to assess global and regional LV
systolic function (1), inadequate definition of the endocardium
may limit the accuracy of these measurements (2,3). A rapid
and easily implemented method to enhance the visualization of
the endocardium and therefore to improve the echocardio-
graphic assessment of LV volumes and ejection fraction (EF)
would be useful.
Recently intravenous (IV) contrast agents (composed of
microbubbles that traverse the pulmonary circulation) have
been used to opacify the LV cavity and improve endocardial
border definition during transthoracic echocardiography (4–
6). However, it is not known whether this contrast-enhanced
border is the true endocardial surface or whether its visualiza-
tion improves the assessment of LV systolic function. Accord-
ingly, the purpose of this study was to determine whether
contrast-enhanced echocardiography improves the evaluation
of LV volumes and EF. To accomplish this, echocardiographic
data acquired before and after IV contrast were compared with
quantitative assessments obtained by gated cine magnetic
resonance imaging (MRI). Because cardiovascular MRI as-
sessments of LV volumes (7,8), EF (9) and regional wall
motion (10) are three-dimensional, noninvasive, accurate and
reproducible, they served as an ideal reference standard for
this study.
Methods
Study population. The study was approved by the Institu-
tional Review Boards at the University of Texas Southwestern
Medical Center at Dallas and the Dallas Veterans Adminis-
tration Medical Center. All participants gave written informed
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consent. The study population consisted of 40 subjects (29 men
and 11 women, aged 24 to 81 years) referred for routine
transthoracic echocardiography for the assessment of LV
systolic function. The original plan was to consecutively enroll
at least 12 subjects in each of 3 categories: 1) normal LV shape
and systolic function, 2) normal LV shape and depressed
systolic function and 3) abnormal LV shape (two or more
contiguous segments with dyskinesia) and depressed systolic
function. However, several patients were subsequently reclas-
sified after the MRI, leaving only nine subjects in the latter
group. Patients were ineligible for the study if they had an
indwelling pacemaker, intracranial clips, intraauricular or in-
traocular implants, a history of metal fragments in the eye,
claustrophobia, marked ventricular ectopy, pregnancy, acute
myocardial infarction within 3 months, atrial fibrillation, obe-
sity (.130% of ideal body weight) with concomitant obstruc-
tive sleep apnea, obstructive or restrictive lung disease, unsta-
ble neurologic disease or an unstable medical condition that
precluded transport from an intensive care unit.
Study design. After establishment of a 20 G IV catheter in
the right antecubital fossa, each subject underwent MRI
followed immediately by transthoracic echocardiography, first
without and then with contrast agent. Heart rate and systemic
arterial pressure were monitored and recorded during MRI
and echocardiography. All data, including heart rate, blood
pressure, LV volumes, EF and regional wall motion determi-
nations were compiled, analyzed and stored without knowl-
edge of the findings obtained during the other procedure. To
ensure blinded interpretation of the data, images were not
labeled with the patient’s name, but rather with a number
derived from a randomization table before the study.
Magnetic resonance imaging technique. Magnetic reso-
nance imaging was performed with a 1.5-T Philips NT whole-
body imaging system (Philips Medical Systems, Shelton, Con-
necticut). Each patient was positioned supine on the MRI
table with electrocardiographic (ECG) monitoring leads at-
tached. All MRI scans used prospective ECG gating. The
apical two- and four-chamber views were positioned using the
Planscan software, according to previously published tech-
niques (8,11). The two-chamber view was parallel to the
interventricular septum and intersected the cardiac apex and
midmitral valve; the four-chamber view was perpendicular to
the interventricular septum, maximizing right ventricular size
and intersecting the apex and midmitral valve. Left ventricular
volume and EF measurements were calculated from a series of
multislice, multiphase gradient-echo sequences positioned per-
pendicular to the long axis of the left ventricle (short axis),
spanning apex to base. The apical and short-axis slices were
9 mm thick (short-axis slices separated by a 1-mm gap) with a
256 3 256 matrix, a temporal resolution of 40 ms, a field of
view of 35 cm (yielding voxel sizes of 1.4 3 1.4 3 9 mm), a flip
angle of 40°, a repetition time of 13.7 ms and an echo time of
8.1 ms.
For LV volume measurement the endocardial border of
each slice was planimetered manually at end diastole and end
systole, and volumes were calculated by Simpson’s rule (12).
End diastole was defined as the first frame in each sequence.
To determine end systole, the images were reviewed in cine
format and the frame with the smallest endocardial circumfer-
ence was selected. Basal slices were reviewed in cine format to
resolve structures for inclusion (the aortic outflow tract) or
exclusion (left atrium and mitral leaflets) from the volume
measurements. Magnetic resonance images were stored on
optical disks for subsequent recall and analysis.
Transthoracic echocardiography. Echocardiography was
performed with a Sonos 2500 (Hewlett-Packard Company,
Andover, Massachusetts) using a 2.5-MHz transducer. Each
patient was positioned on the left side with ECG monitoring
leads attached. Gain settings were optimized for each subject
and then not changed throughout the remainder of the proto-
col. Apical two- and four-chamber views of the left ventricle
were acquired at a rate of 30 frames/s, and a single cardiac
cycle was stored as a cine loop on an optical disk. Great care
was taken to avoid apical foreshortening and to maximize the
length from base to apex. Echocardiographic data were ana-
lyzed by an experienced observer (P.G.) who was unaware of
the MRI and clinical data. A second observer (I.A.), who was
unaware of the study design and methods, also read the studies
independently. Left ventricular volumes were determined us-
ing the biplane summation of disks method recommended by
the American Society of Echocardiography (2). All data re-
garding the baseline examination were recorded before begin-
ning the contrast portion of the study.
A weight-adjusted dose (0.5 ml/kg) of 2% dodecafluoropen-
tane (DDFP) emulsion (EchoGen, Sonus Pharmaceuticals,
Bothell, Washington) was used to opacify the LV cavity. This
substance is liquid at room temperature and shifts to a gaseous
phase at body temperature, producing bubbles 3 to 5 mm in
diameter. After it was drawn into a polycarbonate syringe, the
agent was activated by withdrawal and abrupt release of the
plunger against the vacuum provided by a closed stopcock. The
agent was infused intravenously at a rate of 0.5 to 1.0 ml/s
followed by 5 ml of normal saline flush at a rate of 0.5 to
1.0 ml/s. During the intravenous infusion two- and four-
chamber views of the left ventricle were acquired and stored as
cine loops on an optical disk. Assessments of global LV systolic
function were determined and recorded in the same fashion as
the baseline echocardiogram. After 15 min of observation the
patient was discharged.
Data analysis. Without knowledge of the LV function
data, we excluded patients from analysis a priori if heart rate or




EF 5 ejection fraction
IV 5 intravenous
LV 5 left ventricular
MRI 5 magnetic resonance imaging
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echocardiography. The primary end point was quantitation of
LV volumes and EF. We also analyzed semiquantitative as-
sessment of regional wall motion as a secondary end point.
Left ventricular volumes and EF obtained by echocardiog-
raphy with and without contrast agent were compared with
those measured by MRI using linear regression analysis. The
limits of agreement (defined as 62 SDS from the mean
difference) between echocardiographic and MRI measure-
ments of global LV function were compared using the analysis
of Bland and Altman (13). In addition, the absolute differences
between MRI and echocardiographic assessment of LV vol-
umes and EF (before and after contrast agent administration)
were compared using a paired t test. The EF for each patient
was grouped into one of three categories: normal ($50%),
mildly to moderately reduced (35% to 49%) or severely
depressed (,35%). McNemar’s test (14) was used to evaluate
the agreement between both echocardiographic tests (with and
without contrast agent) and MRI for the classification of the
subjects into the proper EF subset. Unless stated otherwise,
data for heart rate, systemic pressure, wall motion assessment,
LV volumes and EF were expressed as mean 6 1 SD. For all
statistical analyses a p value of ,0.05 was considered signifi-
cant.
Results
Clinical data. Magnetic resonance imaging and echocar-
diographic studies were completed in all but three subjects;






Demographics End Diastolic Volume End Systolic Volume Ejection Fraction
Patient Condition Sex/Age Echo Cont. MRI Echo Cont. MRI Echo Cont. MRI Echo Cont.
Group I (normal LV systolic function)
1 Hypertension; dyspnea F/55 No No 64 62 55 21 27 20 0.67 0.56 0.64
2 Hypercholesterolemia; dyspnea M/39 No No 86 79 91 26 20 35 0.70 0.75 0.62
3 Mitral valve prolapse M/44 Yes No 85 102 89 26 49 31 0.69 0.52 0.65
4 Hypertension; dyspnea M/65 Yes No 103 97 96 40 40 45 0.61 0.59 0.53
5 Mitral valve prolapse F/59 Yes Yes 92 109 93 30 41 28 0.67 0.62 0.70
6 Hypertension; dyspnea M/60 No No 79 107 95 29 30 32 0.63 0.72 0.66
7 Mitral regurgitation M/46 No No 203 170 171 71 63 57 0.65 0.63 0.67
8 Mitral regurgitation M/55 Yes No 109 139 87 35 48 36 0.68 0.65 0.59
9 Hypertension; dyspnea M/46 No No 84 100 89 33 27 23 0.61 0.73 0.74
10 Mitral regurgitation F/29 No No 114 98 99 45 30 30 0.61 0.69 0.70
11 Hypertension; dyspnea M/43 Yes No 118 148 122 54 48 47 0.54 0.68 0.61
12 Mitral regurgitation F/24 No No 113 96 118 42 33 35 0.63 0.66 0.70
13 Mitral regurgitation M/75 Yes No 127 106 84 56 27 34 0.56 0.75 0.60
14 Effusive/constrictive pericarditis M/75 No No 67 69 70 33 38 33 0.51 0.45 0.53
15 Coronary atherosclerosis F/53 No No 96 124 110 46 73 50 0.52 0.41 0.55
Group II (abnormal LV systolic function)
16 Ischemic cardiomyopathy M/65 No No 174 199 177 132 151 136 0.24 0.24 0.23
17 Dilated cardiomyopathy F/34 Yes No 154 119 113 100 64 71 0.35 0.46 0.37
18 Ischemic cardiomyopathy M/50 No No 349 336 372 301 257 308 0.14 0.24 0.17
19 Hypertensive cardiomyopathy F/71 Yes No 88 110 101 58 54 67 0.34 0.51 0.34
20 Ischemic cardiomyopathy M/56 Yes No 156 149 116 99 98 75 0.37 0.34 0.35
21 Ischemic cardiomyopathy M/66 Yes No 155 175 141 111 87 93 0.28 0.50 0.34
22 Ischemic cardiomyopathy F/63 Yes No 283 247 226 221 177 183 0.22 0.28 0.19
23 Hypertensive cardiomyopathy M/33 No No 134 159 126 90 106 87 0.33 0.33 0.31
24 Ischemic cardiomyopathy M/58 No No 67 99 84 36 55 52 0.46 0.44 0.38
25 Coronary atherosclerosis M/49 No No 113 169 132 67 99 65 0.41 0.41 0.51
26 Coronary atherosclerosis M/47 Yes No 110 104 110 57 48 61 0.48 0.54 0.45
Group III (abnormal LV systolic function with dyskinesia)
27 Ischemic cardiomyopathy M/57 Yes No 201 193 199 138 125 123 0.31 0.35 0.38
28 Ischemic cardiomyopathy M/61 Yes No 182 212 172 139 124 113 0.24 0.42 0.34
29 Ischemic cardiomyopathy M/78 No No 219 236 244 154 183 179 0.30 0.22 0.27
30 Ischemic cardiomyopathy M/64 No No 131 111 128 94 80 84 0.28 0.28 0.34
31 Ischemic cardiomyopathy M/60 Yes No 186 163 165 140 105 116 0.25 0.36 0.30
32 Ischemic cardiomyopathy M/51 No No 155 147 150 104 113 107 0.33 0.23 0.29
33 Ischemic cardiomyopathy M/81 No No 216 159 205 165 122 146 0.24 0.23 0.29
34 Ischemic cardiomyopathy M/49 No No 118 113 110 76 70 59 0.36 0.38 0.46
35 Ischemic cardiomyopathy M/56 Yes No 136 143 149 79 68 89 0.42 0.52 0.40
Cont. 5 echocardiogram performed with contrast; Echo 5 standard echocardiogram; MRI 5 magnetic resonance imaging examination.
1428 HUNDLEY ET AL. JACC Vol. 32, No. 5
ASSESSMENT OF LV FUNCTION BY CONTRAST ECHO November 1, 1998:1426–32
one had no acoustic window to obtain the apical views with
echocardiography, and two did not receive contrast agent
because IV access was not maintained throughout the MRI
and baseline echocardiographic examinations. Two additional
subjects were excluded from further analysis because heart rate
changed by .10% during echocardiography and MRI. The
remaining 35 subjects formed the study population; their
detailed data are listed in Table 1. The patients’ mean height
was 174 cm (range 152 to 193 cm) and the mean weight was
78 kg (range 61 to 108 kg). In seven subjects the apical
two-chamber view was determined to be foreshortened, and
only data from the four-chamber view were used for global LV
function assessments. After receiving contrast agent, two sub-
jects reported mild side effects lasting ,1 min with no other
sequelae: one noted a headache and the other noted paresthe-
sias. Representative precontrast and postcontrast echocardio-
grams from a subject in this study are shown in Figure 1.
Comparison of echocardiography and MRI. The correla-
tion coefficients between echocardiographic and MRI values
for end diastolic volume, end systolic volume and EF were all
.0.92 (Fig. 2). However, the Bland–Altman plots (Fig. 3) show
that the limits of agreement (95% confidence intervals) be-
tween MRI and echocardiographic measurements of LV end
diastolic volume, end systolic volume and EF narrowed signif-
icantly after IV contrast. This is illustrated in Table 2, which
compares the absolute differences between echocardiographic
and MRI measurements of LV volumes and EF before and
after contrast agent. Before contrast echocardiographic and
MRI EF differed by .0.10 in 11 patients (31%); after contrast
only one patient (3%) with normal LV function had an
absolute difference of .0.10 (chi-square 5 6.75, p , 0.04).
Compared with MRI, contrast echocardiography was supe-
rior to standard echocardiography for the classification of
subjects with EFs ,35%, 35% to 49% and $50% (Fig. 4).
Twenty-five subjects (71%) were correctly classified into ap-
propriate EF subsets with precontrast echocardiography com-
Figure 1. Transthoracic echocardiographic images of the apical four-
chamber view obtained from a patient before (left) and after (right)
the administration of contrast agent. The endocardial border is not
well seen at baseline but becomes readily apparent with contrast
enhancement.
Figure 2. Regression plots showing
the correlation between MRI (hori-
zontal axis) and echocardiography
(vertical axis) for LV end diastolic
volumes (A), end systolic volumes
(B) and EF (C). Data points for
individual patients are displayed as
precontrast values (black squares) or
postcontrast values (black dia-
monds). Open symbols 5 patients in
whom two or more segments were
not seen on the precontrast echocar-
diogram.
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pared with 33 subjects (94%) after contrast (chi-square 5 4.0,
p , 0.03). These findings were more striking in the patients
with two or more adjacent segments not seen on the baseline
echocardiogram.
Interobserver variability. The interobserver variability for
the precontrast echocardiographic measurements of LV end
diastolic and end systolic volumes as well as EF was 4 6 18,
Figure 3. Bland–Altman plots showing the mean difference (solid
lines) and the limits of agreement (dashed lines) between echocardio-
graphic and MRI measurements of LV end diastolic volume (A and B),
end systolic volume (C and D) and EF (E and F). Left 5 baseline
echocardiography; right 5 postcontrast echocardiography. The value
for each patient is represented by a diamond. For each variable the
limits of agreement become more narrow after contrast agent admin-
istration.
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26 6 18 and 0.07 6 0.10 ml, respectively. After contrast these
values were 28 6 20, 210 6 15 and 0.04 6 0.07 ml.
Discussion
Assessment of LV volume, EF and regional wall motion is
valuable for risk stratification in myocardial infarction (15),
coronary artery bypass grafting (16) and valvular heart disease
(17,18). The use of angiotensin-converting enzyme inhibitors
in patients who sustain a myocardial infarction (19) or exhibit
symptoms of heart failure (20) has been shown to prolong
survival in those with severely, as opposed to mildly, reduced
LVEF. Thus, for patients with a variety of cardiovascular
disorders, identification of reduced systolic function and quan-
tification of the magnitude of this reduction has marked
clinical importance. Although images acquired with trans-
thoracic echocardiography may be used to assess LV volumes
and EF, inadequate definition of the endocardium may limit
their accuracy and utility (2). Whether required for clinical or
research purposes, quantitative measures of global and re-
gional LV systolic function in many patients often require
additional forms of testing (angiography, radionuclide scintig-
raphy and, more recently, MRI). Thus, a rapid and relatively
simple method to improve the visualization of the endocardial
border with transthoracic echocardiography, resulting in a
more reliable assessment of LV volumes and EF, would
improve the utility of this widely used versatile imaging mo-
dality.
Rationale for study. Because microbubbles have a high
acoustic impedance and reflect ultrasonic transmissions better
than blood, they can opacify the LV cavity after IV injection
and traversal of the pulmonary circulation. Preliminary studies
of microbubble administration indicate that their use improves
endocardial border definition and reader confidence in wall
motion assessment in subjects with suboptimal visualization of
the LV endocardial surface (4–6,21). However, it is important
to recognize that improved visualization of the LV cavity after
contrast agent administration may not translate into improved
measures of global and regional LV systolic function. Contrast-
induced attenuation artifacts may obscure the endocardial
surface. In addition, accumulation of contrast agent simulta-
neously in the LV myocardium and cavity may reduce visual-
ization of the border between the blood pool and the endo-
cardium. Perhaps more important, microbubbles may slow the
velocity of ultrasound transmission through the cavity, result-
ing in spatial misregistration of the true endocardial surface
(22). Contrast-enhanced echocardiographic assessments of
LVEF have been shown to be similar to those acquired with
routine echocardiography or contrast ventriculography in pa-
tients with high-quality images and preserved LV systolic
function (23). However, no study has rigorously compared the
utility of contrast agent administration for the assessment of
LV volumes and EF in patients with a spectrum of echocar-
diographic image quality, LV shape and systolic performance.
This study is the first to demonstrate that improved LV
endocardial border definition after IV contrast translates into
more accurate measurements of global and regional LV sys-
tolic function.
Clinical findings. Our data allow us to reach several con-
clusions. First, the correlation and limits of agreement between
MRI and echocardiographic determinations of LV volumes
and EF improve after contrast agent administration (Figs. 2
and 3). The more narrow limits of agreement that are noted in
contrast assessments of EF appear related to two factors: 1)
improved assessment of end systolic volumes (Fig. 3, B and D)
and 2) a subtle tendency to draw end diastolic volumes smaller
after IV contrast (Fig. 3, A). The fact that the limits of
agreement between echocardiographic and MRI measure-
ments were more narrow after the administration of contrast
agent is not surprising. It is well known that structures that are
parallel to the ultrasound beam, such as the endocardial
border in the apical views, are difficult to resolve with echo-
Figure 4. The percentage of subjects in which echocardiographic
assessments of global LV systolic function were accurate for the
determination of normal, mildly to moderately depressed or severely
reduced LV systolic function. In subjects with complete visualization of
the endocardium, contrast agent administration was of no benefit;
however, if two or more endocardial segments were not visualized at
baseline, contrast enhancement markedly improved classification of
EF subsets. Open bars 5 standard echocardiography; solid bars 5
contrast echocardiography.
Table 2. Absolute Difference Between Echocardiographic and





Heart rate (min21) 3.0 6 2.3 2.9 6 2.4 0.44
Mean arterial pressure (mm Hg) 4.5 6 4.7 4.9 6 5.0 0.30
End diastolic volume (ml) 21 6 13 15 6 14 0.038
End systolic volume (ml) 17 6 13 12 6 9 0.015
LVEF 0.08 6 0.06 0.05 6 0.03 0.031
All values are mean 6 1 SD. LVEF 5 left ventricular ejection fraction;
MRI 5 magnetic resonance imaging.
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cardiography. Spherical microbubbles in the LV cavity provide
a surface that is perpendicular to the ultrasound beam, have a
large scattering cross section (22) and therefore facilitate
endocardial visualization and tracing of its contour. We did not
encounter failure of the contrast agent to opacify the apex
during systole, as has been seen with first-generation agents.
Second, the improved echocardiographic assessment of LV
systolic function after IV contrast agent administration has
clinical utility for distinguishing between mildly and severely
depressed LVEF. We prospectively chose a cutoff value of
EF , 0.35 because this value has important prognostic impli-
cations in heart failure (20). It is important to point out that
the advantage of contrast echocardiography was most striking
in the subjects with two or more nonvisualized segments on the
baseline echocardiogram. Thus, these data do not support the
use of IV contrast agent to improve quantitation of the left
ventricle in patients in whom all segments can be clearly seen
on the baseline echocardiogram.
Finally, the improved accuracy of contrast-enhanced deter-
mination of EF was most valuable in patients with EF values
between 25% and 50%. We found little clinical utility when the
precontrast EF was $60% or ,25%. In no case did an EF
calculation fall below 50% (our cutoff for mildly depressed LV
systolic function) when the precontrast EF was $60%. Simi-
larly, in patients with a precontrast EF ,25%, contrast echo-
cardiography did not raise the EF above 35%. These findings
held true regardless of the number of segments seen on the
baseline echocardiogram.
Study limitations. Our study has limitations. First, all our
patients were in sinus rhythm. None had frequent ventricular
ectopy or atrial fibrillation. We are uncertain if contrast
provides reliable results in subjects with irregular rhythms.
Second, contrast enhancement may reduce the ability to
visualize the mitral annular plane because of marked opacifi-
cation of both the left atrium and left ventricle in the apical
views. Thus, both readers had to occasionally refer to the
baseline images to identify the mitral annulus. This was done
after all of the baseline data sets had been analyzed in blinded
fashion without knowledge of the contrast-enhanced echocar-
diogram or the MR images. Finally, we used continuous,
two-dimensional, fundamental imaging for the echocardio-
graphic portions of the protocol. Recently it has been shown
that the use of intermittent or second harmonic imaging, or
both, increases the signal/noise ratio for contrast echocardiog-
raphy (24). Thus, improved results may occur with such
techniques. In addition, tissue harmonic imaging enables im-
proved visualization of endocardial borders even without the
use of contrast agent and may reduce the number of patients in
whom contrast agent is needed for quantitation of LV func-
tion.
Conclusions. Intravenous contrast using 2% DDFP emul-
sion during routine echocardiography improves quantification
of LV volumes and EF. These findings are most pronounced in
subjects with incomplete visualization of the endocardium
during precontrast echocardiography.
References
1. Kisslo J. A letter from America. Br Heart J 1994;71 Suppl:28–30.
2. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantita-
tion of the left ventricle by two-dimensional echocardiography. J Am Soc
Echocardiogr 1989;2:358–67.
3. Freeman AP, Giles RW, Walsh WF, Fisher R, Murray IPC, Wilcken DEL.
Regional left ventricular wall motion assessment: comparison of two-
dimensional echocardiography and radionuclide angiography with contrast
angiography in healed myocardial infarction. Am J Cardiol 1985;56:8–12.
4. Porter TR, Xie F, Kricsfeld A, Chiou A, Dabestani A. Improved endocardial
border resolution during dobutamine stress echocardiography with intrave-
nous sonicated dextrose albumen. J Am Coll Cardiol 1994;23:1440–3.
5. Crouse LJ, Cheirif J, Hanly DE, et al. Opacification and border delineation
improvement in patients with suboptimal endocardial border definition in
routine echocardiography: results of the phase III albunex multicenter trial.
J Am Coll Cardiol 1993;22:1494–1500.
6. Feinstein SB, Cheirif J, TenCate FJ, et al. Safety and efficacy of a new
transpulmonary ultrasound contrast agent: initial multicenter clinical results.
J Am Coll Cardiol 1990;16:316–24.
7. Rehr RB, Malloy CR, Filipchuk NG, Peshock RM. Left ventricular volumes
measured by MR imaging. Radiology 1985;156:717–9.
8. Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left
ventricular volume measurement using cardiac axis NMR imaging: valida-
tion by calibrated ventricular angiography. Circulation 1990;82:154–63.
9. VanRossum AC, Visser FC, Sprenger M, VanEenige MJ, Valk J, Roos JP.
Evaluation of magnetic resonance imaging for determination of left ventric-
ular ejection fraction and comparison with angiography. Am J Cardiol
1988;62:628–33.
10. Hundley WG, Li HF, Willard JE, et al. Magnetic resonance imaging
assessment of the severity of mitral regurgitation: a comparison with invasive
techniques. Circulation 1995;92:1151–8.
11. Sayad DE, Willett DL, Bridges WH, et al. Noninvasive quantitation of left
ventricular wall thickening using cine magnetic resonance imaging with
myocardial tagging. Am J Cardiol 1995;76:985–9.
12. Sechtem U, Pflugfelder PW, Gould RG, Cassidy MM, Higgins CB. Mea-
surement of right and left ventricular volumes in healthy individuals with
cine MR imaging. Radiology 1987;163:697–702.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet 1986;1:307–10.
14. Glantz SA. Primer on Biostatistics. 2nd ed. New York: McGraw-Hill Book
Company, 1977. pp 278–9.
15. The Multicenter Postinfarction Research Group. Risk stratification and
survival after myocardial infarction. N Engl J Med 1983;309:331–6.
16. Alderman EL, Bourassa MG, Cohen LS, et al., for the CASS Investigators.
Ten year follow-up of survival and myocardial infarction in the randomized
coronary artery surgery study. Circulation 1990;82:1629–34.
17. Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricu-
lar performance to mitral valve surgery. Circulation 1979;59:1218–31.
18. Crawford MH, Soucheck J, Oprian CA, et al. Determinants of survival and
left ventricular performance after mitral valve replacement. Circulation
1990;81:1173–81.
19. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality
and morbidity in patients with left ventricular dysfunction after myocardial
infarction: results of the Survival and Ventricular Enlargement Trial. N Engl
J Med 1992;327:669–77.
20. SOLVD Investigators. Effect of enalapril on survival in patients with reduced
left ventricular ejection fractions and congestive heart failure. N Engl J Med
1991;325:293–302.
21. Grayburn PA, Hack TC, Weiss JL, et al. A phase III multicenter trial
comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGent)
and sonicated 5% human albumin (Albunext) as ultrasound contrast agents in
patients with suboptimal echocardiograms. J Am Coll Cardiol 1998;32:
230–6.
22. De Jong N, Ten Cate FJ, Lancee CT, Roelandt JRTC, Bom N. Principles
and recent developments in ultrasound contrast agents. Ultrasonics 1991;29:
324–30.
23. Zotz RJ, Genth S, Waaler A, Erbel R, Meyer J. Left ventricular volume
determination using albunex. J Am Soc Echocardiogr 1996;9:1–8.
24. Lindner JR, Dent JM, Moos SP, Jayaweera AR, Kaul S. Enhancement of left
ventricular cavity opacification by harmonic imaging after venous injection of
albunex. Am J Cardiol 1997;79:1657–62.
1432 HUNDLEY ET AL. JACC Vol. 32, No. 5
ASSESSMENT OF LV FUNCTION BY CONTRAST ECHO November 1, 1998:1426–32
